US FDA Approves Takeda’s Livtencity Drug For Treating Post-Transplant Cytomegalovirus (CMV) Infection

Takeda Pharmaceutical has announced that, the US FDA has given the approval to the Livtencity (maribavir) drug for the purpose of treating the adults and the pediatric patients suffering from the post-transplant CMV infection that is having a refractory to the treatment with ganciclovir, cidofovir, foscarnet or valganciclovir. More than double the proportion of the […]

Continue Reading